-
Philips and SAM to open oncology center in Singapore
biospectrumasia
July 11, 2017
The new research, training and treatment center will provide cutting-edge oncology solutions for use by healthcare professionals and researchers.
-
Sayre Therapeutics in license and distribution agreement with Navidea Biopharmaceuticals
financialexpress
June 30, 2017
To develop and commercialise Tc 99m tilmanocept in India
-
Glenmark Pharmaceuticals licenses small molecule oncology compound from APC Therapeutics to expand I
cphi-online
June 23, 2017
The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.
-
IBM Announces Partnership with Baheal Group to Bring Watson for Oncology to China
en-cphi.cn
June 07, 2017
Consistent with its mission to improve and save lives, Baheal will extend the reach of Watson for Oncology across China, where a quarter of the world's cancer deaths occur
-
Bayer Adds Oncology Leadership
contractpharma
June 07, 2017
Rebecca Jolley has been appointed senior vice president and commercial head of Oncology at Bayer, and Dr. Scott Z. Fields was named senior vice president and pharmaceutical development head, Oncology.
-
Guardant Health in long-term association with Pfizer Oncology to support several clinical programs
biospectrumasia
June 07, 2017
Guardant360 assay will be the preferred circulating tumor DNA (ctDNA) test for liquid biopsy specimens collected in various Pfizer clinical trials after this non-exclusive agreement.
-
LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program
b3cnewswire
April 12, 2017
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism.
-
Median Technologies partners with inVentiv Health
biospectrumasia
April 11, 2017
Median, a leading services provider for image interpretation and management in oncology trials, will complement inVentiv Health's comprehensive oncology solutions.
-
Nimbus Therapeutics, Charles River in Strategic R&D Alliance
contractpharma
April 07, 2017
Will work to advance programs in immunology, metabolic disorders and oncology from discovery through to IND
-
Charles River Launches Oncology Research Model
contractpharma
April 05, 2017
Charles River Laboratories has launched its triple-immunodeficient mouse model, known as the NCG model. The NCG model is the first CRISPR-generated immunodeficient model offered by the company, and was developed by altering the Prkdc and Il2rg genes.